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ABSTRACT 
Syndecans are a four-member family of transmembrane heparan sulfate 
proteoglycans that have different functions in cell signalling, adhesion, cytoskeleton 
organization, migration, proliferation and angiogenesis. Several studies investigated the 
role of syndecan-2 (SDC2) in different carcinomas, however, only one being focused on 
SDC2 in prostate cancer.  
SDC2 expression and relationship with established prognostic features were 
assessed in a cohort of 86 patients treated with radical prostatectomy for clinically 
localized prostate adenocarcinoma. 
SDC2 expression was present in the majority of prostate cancers and absent in 
only 11.6% of cases. SDC2 expression was also recorded in cells of prostatic 
intraepithelial neoplasia, whereas normal prostatic epithelial tissue and stroma did not 
express SDC2. SDC2 overexpression in prostate cancer was significantly associated 
with established features indicative of worse prognosis such as higher preoperative PSA 
(p=0.011), higher Gleason score (p<0.001), positive surgical margins (p<0.003), and 
extraprostatic extension of disease (p<0.003). Moreover, expression of SDC2 was also 
associated with biochemical disease progression on univariate analysis (p<0.001). 
Study results supported the potential role of SDC2 in prostatic carcinogenesis 
and cancer progression. Moreover, SDC2 could serve as an additional prognostic 
marker that might help in further stratifying the risk of disease progression in patients 
with prostate cancer. 
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INTRODUCTION  
 Syndecans are a four-member family of transmembrane heparan sulfate 
proteoglycans expressed on the surface of many different adherent and non-adherent 
cells. Syndecans are composed of a short C-terminal cytoplasmic domain, an N-terminal 
signal peptide, an ectodomain containing several consensus sequences for 
glycosaminoglycan attachment, and a transmembrane domain with a putative protease 
cleavage site at the proximal side.1,2  
 Within the family, the extracellular domain sequences are molecule specific, but 
the transmembrane and cytoplasmic domain are highly conserved, implying the 
possibility of conserved biological role. Despite the high homology observed in the 
cytoplasmic domain, each syndecan has its own unique function that is attributed to 
differences in amino acid sequences in the middle of the cytoplasmic domain.2-5 
 Syndecans have different functions ranging from cell-cell and cell-extracellular 
matrix adhesion to the regulation of heparan sulfate-binding growth factor activity and 
tyrosine kinase signalling pathway as well as cytoskeleton organization, migration, 
proliferation and angiogenesis.1-6 
 Syndecan-2 (SDC2) was originally biochemically characterized as one of the 
major heparan sulfate glycosaminoglycans containing cell surface proteins expressed in 
lung fibroblasts.7 Early recognizable role of SDC2 was cell adhesion and migration but 
recently SDC2 has also been implicated in the tyrosine kinase signalling pathway 
activation, cancer progression and angiogenesis.8-12 Several studies investigated the role 
of SDC2 in different carcinomas13-15, however, only one was focused on SDC2 in 
prostate cancer.16  
 SDC2 expression and relationship with established prognostic features were 
assessed in a cohort of 86 patients treated with radical prostatectomy for clinically 
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localized prostate adenocarcinoma, in order to determine the expression and prognostic 
value of SDC2 in prostate cancer. 
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PATIENTS AND METHODS 
Patients 
 The study included 86 consecutive patients, median age 65.0 (range 52-74, 
interquartile range 61-68) years, treated with radical retropubic prostatectomy and 
bilateral lymphadenectomy for clinically localized prostate adenocarcinoma at 
University Department of Urology, Sestre milosrdnice University Hospital, Zagreb, 
between January 1, 2002 and December 31, 2003. All patient identifiers were removed 
and replaced by unique study numbers, linked to the original identifiers by a single file 
kept under high security. A minimum of 60 months of follow up and the retrieval of 
archival tissue block was conducted under institutional review board approval.  
 After radical prostatectomy, patients were scheduled for clinical examination 
and serum prostate specific antigen (PSA) evaluation every three months for the first 
year, semi-annually from the second year, and annually thereafter. The study end point 
(time of recurrence) was defined as two consecutive rising serum PSA values greater 
than 0.2 ng/mL.  
 Overall follow up ranged from 6 to 84 (median 64.5, interquartile range 28-72) 
months. Thirty of 86 (34.9%) patients had biochemical disease progression with a 
median time of progression of 18.5 (range 6-63, interquartile range 9-30) months.  
 Preoperative PSA ranged from 4.2 to 24.4 ng/mL (median 8.65, interquartile 
range 6.6-12.3), and PSA of biochemical disease progression ranged from 0.3 to 3.2 
ng/mL (median 0.99, interquartile range 0.6-1.7).   
 The clinical stage was assigned by the operative surgeon according to the criteria 
of the International Union against Cancer.17 The Gleason distribution with Gleason 
patterns is shown in Table 1. Overall, 22 of 86 (25.6%) patients had extraprostatic 
extension of disease; 12 (54.4%) of them had extension through the capsule, 5 (22.8%) 
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had seminal vesicle invasion, and 5 (22.8%) had both extension through the capsule and 
seminal vesicle invasion. Only two patients had metastases to lymph nodes. None of the 
patients was treated with hormone or radiation therapy before or after radical 
prostatectomy, and none had secondary cancer. 
 
Methods 
 Specimens were fixed in 10% buffered formalin, embedded in paraffin, cut at 5-
mm thickness, and routinely stained with haematoxylin and eosin. The diagnosis of 
adenocarcinoma was histologically confirmed in all cases.  All slides submitted to 
immunohistochemistry analysis were so chosen that Gleason patterns in the slides most 
closely recapitulated postoperative Gleason score and also contained areas of non-
neoplastic prostate tissue.  
 Deparaffinization and immunohistochemical staining were performed following 
the Microwave Streptavidin ImmunoPeroxidase (MSIP) protocol on a DAKO Tech-
MateTM Horizon automated immunostainer (DAKO, Copenhagen, Denmark). We used 
primary monoclonal antibodies to syndecan-2 ((1F10/B8): sc-73516, dilution 1:100, 
Santa Cruz Biotechnology, Inc., CA, USA). Colon cancer tissue served as a positive 
control and removal of the primary antibody was used as a negative control. 
 To evaluate the intensity of SDC2 expression in prostate cancer, the percentage 
of positively stained carcinoma cells was examined in the whole amount of tumour on 
the chosen slide. The staining intensity was graded on a 0-3 scale and expressed as 0, up 
to10% of positive carcinoma cells; low, more than 10%-25% of positive carcinoma 
cells; moderate, more than 25%-50% of positive carcinoma cells; and high, more than 
50% of positive carcinoma cells. We applied a scanning system similar to that used in 
previous studies of syndecan-1 (SDC1) expression in prostate cancer, where an at least 
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moderate staining intensity was required in more than 10% of tumour cells to define 
SDC2 overexpression.18,19 All samples were examined independently by three observers 
(A. D., B. K. and D. T.), and any difference was resolved by a joint review. 
 Statistical analysis was performed using Mann-Whitney U test, Kruskal-Wallis 
test, χ2-test, Kaplan-Meier test and Cox proportional-hazards regression test. The levels 
of statistical significance were set at least at p<0.05. 
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RESULTS 
 Syndecan-2 was overexpressed in 66 (76.7%) prostate cancer (Fig. 1A). Twenty 
one (24.4%) had low, 18 (20.9%) moderate and 27 (31.4%) high intensity of 
overexpression. Immunohistochemical reaction was membranous and 
intracytoplasmatic, granular (Fig. 1B). Twenty (23.3%) prostate cancers showed no 
overexpression, and 10 (11.6%) of them showed no reaction for SDC2. In benign 
glands, expression was not observed but some glands with prostatic intraepithelial 
neoplasia (PIN) showed reaction to SDC2 (Fig. 1C). Prostate stromal cells did not 
express SDC2, and any staining in the stroma was considered background 
immunoreactivity. 
 Patient age was not significantly different between the patients with and without 
SDC2 overexpression (p=0.499).  
 The patients with SDC2 overexpression had a significantly higher level of 
preoperative PSA (p=0.011). Preoperative PSA positively correlated with the intensity 
of SDC2 expression (p=0.048). 
 Gleason score was significantly higher in patients with SDC2 overexpression 
(p<0.001). Among patients with Gleason score 7, those with score 7 (4+3) had a higher 
rate of SDC2 overexpression than those with score 7 (3+4) (p=0.045). Comparison of 
Gleason score and intensity of SDC2 overexpression showed no correlation (p=0.061).  
 All 22 (100%) patients with extraprostatic extension and 44 (68.7%) patients 
without extraprostatic extension of disease had SDC2 overexpression. Extraprostatic 
extension of disease was more frequently observed in patients with SDC2 
overexpression (p<0.003), in particular those with high intensity of overexpression 
(p<0.021). Disease extension through the capsule correlated with SDC2 overexpression 
(p=0.011), whereas extension to seminal vesicles showed no such correlation (p=0.064). 
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 None of the patients without SDC2 overexpression had biochemical disease 
progression. Disease free period was significantly reduced with the intensity of SDC2 
overexpression and patients with moderate SDC2 overexpression had shortest disease 
free period on univariate analysis (p<0.001) (Fig. 2).  
 On multivariate analysis, SDC2 overexpression was not associated with disease 
free period (p=0.96), while the most significant prognostic factors for biochemical 
disease progression were preoperative PSA (p=0.013) and extraprostatic extension of 
disease (p<0.001). 
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DISCUSSION 
 Several studies investigated syndecans in prostate cancer, but were mostly 
focused on syndecan-1 (SDC1)18-21, and only one addressed expression of SDC2.16 
Contreras et al.16 found SDC2 to be expressed in normal prostate tissue, benign 
prostatic hyperplasia (BPH), PIN and prostate cancer. In BPH, SDC2 was expressed in 
plasma membrane of epithelial cells, in particular basal cells, and in the basolateral zone 
of secretory cells. In PIN regions, a high intensity staining was found in basal cells. In 
prostate cancer, membrane and granular cytoplasmic staining was observed in most 
cases.16 
 In our study, SDC2 was expressed in the membrane and cytoplasm of the 
majority of prostate cancer cases, with only 11.6% of cases showing no expression, 
which is similar to the study conducted by Contreras et al.16 SDC2 expression was also 
observed in some epithelial cells of PIN lesions but normal prostatic epithelial tissue 
and prostatic stroma did not express SDC2. These results are opposite to those reported 
by Contreras et al.16, where reaction in PIN was located in basal cells, whereas 
nonmalignant epithelial cells also showed SDC2 reactivity in a somewhat similar 
pattern as described for SDC1 by Chen et al.21 
 Our results on SDC2 expression in prostate were consistent with previous 
reports on SDC2 expression in colon carcinoma cells. Normal colon epithelial cells did 
not express SDC2, whereas colon carcinoma cells showed SDC2 up regulation resulting 
in an increased SDC2 expression that proved crucial for tumorigenicity.9,11,14 Park et 
al.14 demonstrated SDC2 to be necessary for cell cycle progression and cell-matrix 
interaction in colon cancer cells. Moreover, an increased level of SDC2 led to a less 
adhesive phenotype and loss of contact inhibition.12,13 These results could point to two 
conclusions; first, normal colon epithelial cells might acquire SDC2 expression 
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activities during carcinogenesis, and second, expression of SDC2 is necessary for 
tumourigenic activity.9,12 
 Syndecan-2 may function in colon cancer cells by at least two different 
mechanisms. First, increased expression of SDC2 may be related to the loss of cell-
extracellular matrix interaction and contact inhibition. Second, SDC2 may be necessary 
for tumour angiogenesis, acting as a co-receptor for signalling molecules important for 
vascular proliferation, such as VEGF, EphB2 or FGF-2. Both mechanisms could 
contribute to tumour growth and metastatic potential of cancer cells.2,9-12   
 A similar role of SDC2 could be proposed in prostate cancer because normal 
epithelial cell did not express SDC2, whereas its expression appeared in cells of PIN 
lesions and carcinoma, indicating SDC2 activities during carcinogenesis. 
 In our study, SDC2 overexpression in prostate cancer was significantly 
associated with established features indicative of worse prognosis such as higher 
preoperative PSA, higher Gleason score, positive surgical margins, and extraprostatic 
extension of the disease. Moreover, SDC2 expression was also associated with 
biochemical disease progression on univariate analysis.  
 Contreras et al.16 report a decreased SDC2 expression in carcinoma with high 
Gleason score (>7). This result could indicate better prognosis for patients with SDC2 
expression. Our results were somewhat different, as the expression of SDC2 positively 
correlated with Gleason score and was an indicator of worse prognosis.  
 Similar results have been previously reported for SDC1.18,19,21 Zellweger et al.18, 
Shariat et al.19 and Chen et al.21 found SDC1 expression to be decreased in prostate 
cancer compared with the adjacent normal cells. However, within prostate cancer areas, 
SDC1 expression was associated with established features that indicated worse 
prognosis such as higher preoperative PSA levels, higher Gleason score, metastases to 
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regional lymph nodes, extraprostatic extension of disease and shorter biochemical 
disease free period.18,19,21 Conversely, Kiviniemi et al.20 and Contreras et al.16 found an 
inverse correlation between SDC1 expression and Gleason score in their small study 
samples of 23 and 45 patients, respectively. 
 A recent study by Shimada et al.22 showed that silencing of SDC1 in prostate 
cancer cell caused significant inhibition of vascular endothelial growth factor and 
tumour angiogenesis. Moreover, SDC1 was also involved in the process of androgen-
dependent to androgen-independent conversion in prostate cancer and could be a new 
target molecule for hormone resistant prostate cancer therapy.22 
 To our knowledge, prognostic utility of SDC2 was only analyzed in oesophageal 
squamous cell carcinoma, where altered SDC2 expression was associated with lymph 
node metastasis, TNM stage and patient survival time, and served as an independent 
prognostic factor for survival.15 
 Our results supported the potential role for SDC2 in prostatic carcinogenesis and 
cancer progression. Moreover, SDC2 could serve as an additional prognostic marker 
that might help in further stratifying the risk of progression in patients with clinically 
localized prostate cancer. Additional studies are necessary to identify SDC2 function in 
prostatic carcinogenesis and its prognostic role in prostate cancer. Better understanding 
of the biological effect of this proteoglycan may help develop targeted therapeutics to 
block its function, thus to ensure normal cellular differentiation and interaction in 
prostatic tissue. 
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Table 1. Gleason distribution with Gleason patterns in 86 patients with prostate 
cancer 
 
 
Gleason score Number of patients 
 
6 (3+3) 28 (32.6%) 
7 (3+4) 35 (40.6%) 
7 (4+3) 21 (24.4%) 
8 (3+5) 1 (1.2%) 
8 (5+3) 1 (1.2%) 
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Figure 1. (A) Syndecan-2 (SDC2) was expressed in prostate cancer while benign 
glands and prostatic stroma showed negative reaction for SDC2 (X100); (B) 
immunohistochemical reaction was membranous and granular, intracytoplasmic 
(X400); (C) in some glands with prostatic intraepithelial neoplasia reaction to SDC2 
was also observed (X400). 
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Figure 2. Impact of syndecan-2 overexpression on the disease free period in patients 
with prostatic carcinoma (Kaplan-Meier survival curve). 
 
 
 
 
 
